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Abstract
A subset of patients with Ewing’s sarcoma responds to anti-insulin-like growth factor-1 receptor (IGF-1R) antibodies.
Mechanisms of sensitivity and resistance are unknown. We investigated whether an anti-IGF-1R antibody acts via a pathway
that could also be suppressed by small interfering (si) RNA against the EWS/FLI-1 fusion protein, the hallmark of Ewing’s
sarcoma. The growth of two Ewing’s sarcoma cell lines (TC-32 and TC-71) was inhibited by the fully human anti-IGF-1R
antibody, R1507 (clonogenic and MTT assays). TC-32 and TC-71 cells express high levels of IGF-2, while RD-ES and A4573
Ewing’s cell lines, which were less responsive to R1507 in our assays, express low or undetectable IGF-2, respectively. TC-71
cells also expressed high levels of IGF-1R, and R1507 decreased steady-state levels of this receptor by internalization/
degradation, an effect which was associated with a decrease in p-IGF-1R, p-IRS-1, and p-Akt. EWS/FLI-1 siRNA also decreased
p-Akt, due to its ability to increase IGF-BP3 levels and subsequently decrease IGF-1 and IGF-2 levels, thus inhibiting signaling
through p-IGF-1R. This inhibition correlated with growth suppression and apoptosis. The attenuation of Akt activation was
confirmed in TC-71 and HEK-293 (human embryonic kidney) cells by transfecting them with IGF-1R siRNA. We conclude that
antibodies and siRNA to IGF-1R, as well as siRNA to EWS/FLI-1, act via intersecting IGF/IGF-1R signals that suppress a
common point in this pathway, namely the phosphorylation of Akt.
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Introduction
Ewing’s sarcoma is an aggressive small round blue-cell tumor that
arises in the bone and soft tissue of young patients [1,2]. Eighty-five
percent of Ewing’s sarcomas contain the t(11;22)(q24;q12) recipro-
cal chromosomal translocation, which results in the generation of a
novel fusion protein combining the N-terminal transactivation
domain of the Ewing’s sarcoma breakpoint region 1 gene (EWSR1)
and the C-terminal DNA binding domain of an ETS (E26
transformation-specific) family member gene [3], most commonly
the FLI-1 (Friend leukemia integration 1) transcription factor gene.
EWS/FLI-1 is a potent transcription factor and has been shown to
both repress and activate specific target genes and function as an
oncoprotein [3].
Therapy of Ewing’s sarcoma includes surgery, radiation, and
systemic chemotherapy in various combinations [1]. A subset of
patients with Ewing’s sarcoma have remarkable responses to
insulin-like growth factor-1 receptor (IGF-1R) inhibitors [4–9],
including the fully human anti-IGF-1R antibody, R1507 [4]. Why
some patients respond, and what factors underlie resistance remains
unclear. Preclinical studies suggest that levels of the IGF/IGFR
machinery might be a factor in response and resistance [10]. We
therefore characterized the status of various molecules important in
the IGF signaling pathway in four Ewing’s sarcoma cell lines,
investigated their response to the anti-IGF-1R antibody R1507, and
explored the relationship between the EWS/FLI-1 fusion protein
and the IGF machinery, including signaling molecules downstream
of the IGF-1R in Ewing’s sarcoma. We demonstrate that the anti-
IGF-1R antibody (R1507) and small interfering RNA (siRNA)
against the Ewing’s fusion protein (EWS/FLI-1) suppress a common
pathway involving the IGF/IGFR/Akt axis through inhibition of
different targets in the IGF/IGF-1R cascade.
Materials and Methods
Cell lines
RD-ES is a Ewing’s sarcoma cell line obtained from American
Type Culture Collection (ATCC). A4573, TC-32, and TC-71
were a generous gift of Dr. Jeff Toretsky [11]. HEI-193 (human
schwannoma), SK-N-AS (human neuroblastoma from ATCC),
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HEK 293 (human embryonic kidney from ATCC), and MCF7
(human breast cancer from ATCC) cell lines were used as non-
Ewing’s sarcoma controls. The HEI-193 cell line was generously
provided by the House Ear Institute [12]. All cell lines were
maintained in RPMI-1640 (GIBCO/BRL) or DMEM plus 10%
fetal calf serum (FCS) and maintained in a 37uC incubator with
5% CO2.
Reverse Transcription-Polymerase Chain Reaction
(RT-PCR)
RT-PCR was performed to confirm the type of EWS/FLI-1
fusion protein in the Ewing’s sarcoma cell lines. Briefly, RNA was
extracted from cell lines using the RNeasyTM mini kit (Qiagen)
and used for reverse transcription followed by PCR using primers
(Sigma-Genosys) as described [13–15]. PCR products were run on
agarose gels, stained with ethidium bromide, and photographed
(Alpha Innotech).
Sequencing of IGF-2R ligand binding domain
To analyze IGF-2R polymorphisms, genomic DNA was
extracted from Ewing’s sarcoma cell lines using the QIAmp
mini-prep kit (Qiagen). PCR primers were designed for exons 27–
40 (IGF-2 ligand binding domain) of IGF-2R (SeqWright, Inc.,
Table S1). PCR reactions were conducted with HotStar HiFidelity
PCR Kit (Qiagen) according to the manufacturer’s protocol. PCR
reactants were purified with QIAquick spin columns (Qiagen) and
sent to SeqWright, Inc. for sequencing. Other regions of the IGF-
2R gene were also studied [16]. Polymorphisms were detected by
comparing generated DNA sequences to reference sequences
(NM_000876.2, NT_007422.13, and NW_001838991.2) using the
web-based software blast.ncbi.nlm.nih.gov/Blast.cgi.
Antibodies and Reagents
R1507, a fully human IgG1 monoclonal antibody to IGF-1R,
(Roche Diagnostics, Penzberg, Germany), was diluted in medium
immediately before use. Recombinant (r) IGF-BP3 and rIGF-1
were purchased from Sigma. Primary antibodies included rabbit
polyclonal antibody against ERK1/2, p-ERK1/2, IGF-1Rb,
phosphorylated (p)-IGF-1R (Tyr 1135/1136), Akt, and p-Akt,
(ser 473) (Cell Signaling), anti -IRS-1 and -p-IRS-1 (Tyr 612)
(Upstate Cell Signaling Solutions), anti-EWS, -IGF-2, -IGF-2R,
and -GAPDH (Santa Cruz Biotechnology). Secondary antibodies
for Western blot included anti-rabbit, anti-mouse, (BioRad), and
goat anti-human conjugated to horse radish peroxidise (HRP)
(Millipore-Chemicon).
Western blot analysis
Cells were seeded in six well plates and treated as described in
the figure legends. For cytoplasmic proteins, cells were washed
with PBS and lysed in 16RIPA buffer (Millipore) plus protease
inhibitors. For EWS/FLI-1, nuclear extracts were obtained by
incubating for 15 minutes in lysis buffer (0.3% NP-40) followed by
30 minutes in ice-cold extraction buffer plus protease inhibitors. A
modified Lowry protein assay was performed (Pierce Biotechnol-
ogy), and equal amounts (20–50 mg) of protein were loaded onto
SDS-PAGE gels. Proteins were transferred to nitrocellulose
membranes by electro-blotting, incubated with primary antibody
at room temperature for two hours, or at 4uC overnight, washed,
and then incubated with secondary antibody conjugated to HRP
and detected by enhanced chemiluminescence (Amersham
Pharmacia Biotech). Blots were exposed to film and densitometry
was performed using a Hewlett Packard scanner and the NIH
Image software (Scion Corporation).
ELISA
Enzyme-linked immunosorbent assays (ELISAs) included free
IGF-1 and IGF-BP3 (R&D Systems), and IGF-2 (Diagnostic
Systems Laboratories). Cells were seeded in six well plates for 24
or 48 hours, supernatants were collected, and ELISA was
performed. The mean lower limits of sensitivity were 0.026 ng/
ml and 2.2 ng/ml for the IGF-1 and IGF-2 ELISAs, respectively.
Because of the low concentration of IGF-BP3 in the Ewing’s
cell lines, supernatants were concentrated 406 using Amicon
centrifugal filter units (Millipore) prior to ELISA. The mean
lower limit of sensitivity for this assay was 0.05 ng/ml.
Absorbance was read using a plate reader (Molecular Devices)
at 570 nm.
Clonogenic assay
Clonogenic assays were performed to determine the effect of
R1507 antibody and EWS/FLI-1 siRNA on Ewing’s sarcoma cell
growth. 16103 cells per well of a 6 well plate coated with 1%
gelatin were seeded in media containing 10% FCS, and either
treated with a single dose of 1–50 mg/ml R1507 or transfected
with EWS/FLI-1 siRNA and allowed to grow for 1 week. Colonies
were counted and compared to untreated control dishes, which
were assigned a value of 100% growth.
MTT assay
Survival of the cells was assessed by MTT (3-[4,5-dimethylthia-
zol-2-yl]2,5-diphenyltetrazolium bromide) assay, according to the
manufacturer’s instructions (Sigma-Aldrich). After 48 hours of
incubation, conversion of MTT was measured at 570 nm and is
expressed as the change in cell growth as compared to untreated
(control) cultures, which were assigned 100% growth.
Annexin V apoptosis assay
Apoptosis of Ewing’s sarcoma cells was measured by staining
cell-surface phosphatidyl serine with FITC-conjugated Annexin V.
56105 (R1507 treated) and 2.56105 cells (siRNA transfected) were
seeded per well of a 96 well plate and treated for 48, 72, or
96 hours, harvested, and stained with FITC-Annexin V and
propidium iodide according to the manufacturer’s instructions (BD
Pharmingen). Cells were analyzed by fluorescence activated cell
sorter (FACS) analysis (Becton Dickinson, Bedford, MA).
siRNA transfection
2.56105 TC-71 or HEK 293 cells were seeded per well of a 6
well plate and transfected with DharmaFECT 1 siRNA lipid
transfection reagent alone (Thermo Scientific Dharmacon), non-
targeted siRNA (siGENOME non-targeting siRNA #1), human
EWS/FLI-1 (EWSR1) siRNA, IGF-1R siRNA, or GAPDH
siRNA (control) for 48 hours. Following transfection, cell lysates
and culture supernatants were harvested for Western blot analysis
and ELISA, respectively.
Statistical analyses
Descriptive statistics were used to summarize the data.
Statistical significance of the differences between continuous
variables was calculated using Student’s t tests or Mann-Whitney
tests, depending on the normality of the data. Comparisons
between three or more groups were analyzed for statistical
significance using an analysis of variance test (one-way ANOVA)
with contrast between pairs of groups when appropriate. P values
lower than 0.05 were considered statistically significant. Analyses
were made using SPSS version 16 (SPSS Inc., Chicago, IL).
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Results
Confirmation of EWS/FLI-1 fusion protein type
A4573, RD-ES, TC-32, and TC-71 Ewing’s sarcoma cell lines
all contain the EWS/FLI-1 translocation t(11;22)(q24;q12). RT-
PCR confirmed that A4573 expresses the type 3 fusion protein,
RD-ES expresses type 2, and TC-32 and TC-71 express type 1
(Figure 1a) [17–19]. Amplification of messenger RNA from the
SK-N-AS (neuroblastoma) cell line using b-actin primers was used
as a positive control for the RT-PCR reaction (Figure 1a, lane 2).
HEI-193 (human schwannoma) was used as a non-Ewing’s
sarcoma control and contains no EWS/FLI-1 fusion protein
(Figure 1a lane 7). Figure 1b shows the different types of fusion
proteins predicted from variable exon joining of the EWS and
FLI-1 genes. All four cell lines expressed the EWS/FLI-1 fusion
protein at similar levels by Western blot (data not shown).
Baseline IGF-1R, p-IGF-1R, IRS-1, and p-IRS-1 expression
levels
In order to determine if there was a correlation between IGF
family member expression with response to anti-IGF-1R antibody
treatment, Western blot and ELISA was performed to quantify the
relative expression of these molecules at baseline. IGF-1R is a
tyrosine kinase receptor that binds IGF-1 and -2 with high affinity.
Baseline expression levels of IGF-1R and p-IGF-1R were
examined by Western blot (Figure 1c). Expression of total IGF-
1R was highest in TC-71 and A4573, followed by TC-32 and RD-
ES cells, as determined by densitometry. A4573 and TC-71 cells
expressed the highest levels of p-IGF-1R (Figure 1c). Insulin
receptor substrate protein-1 (IRS-1) is an important signaling
molecule downstream of IGF-1R, and its phosphorylation has
been implicated in increased cell proliferation and survival via the
phosphoinositide-3 kinase (PI3K)/Akt pathway [20,21]. RD-ES,
TC-32, and TC-71 expressed similar baseline levels of total IRS-1,
while A4573 contained the least (Figure 1d). TC-32 and TC-71
expressed the most p-IRS-1 followed by RD-ES, then A4573.
Note that the level of p-IGF-1R and p-IRS-1 does not always
correlate within individual cell lines (Figure 1c and d). MCF7 and
HEK293 cells were used as positive control cell lines for expression
of IGF family members.
IGF-2 levels, IGF-2R expression, and IGF-2R gene
polymorphisms in the IGF-2 binding domain
The IGF-2/mannose-6-phosphate receptor (IGF-2R/M6PR)
binds and internalizes IGF-2, thereby attenuating IGF-2’s ability
to signal through IGF-1R, the primary signaling receptor.
Mutations in IGF-2R have been found in many types of cancer
(see Discussion), and may predict response to IGF-1R inhibitors.
Certain mutations reduce the amount of IGF-2R expressed on the
cell surface, and increase the amount of free IGF-2, thereby
allowing enhanced signaling through IGF-1R. IGF-2R expression
was lower in TC-32 and TC-71 cells compared with A4573 and
RD-ES cells. This may partially account for the higher levels of
IGF-2 seen in the culture supernatant of these cells (Figure 1c).
A4573 cells contain the G.A single nucleotide polymorphism
(SNP) (GA) at nucleotide position 5004 in the IGF-2R cDNA,
Figure 1. EWS/FLI-1 fusion protein type and baseline expression levels of IGF-1 signaling molecules in Ewing’s sarcoma and control
cell lines. (a) RT-PCR of the EWS/FLI-1 fusion protein transcripts was performed using mRNA from four different Ewing’s sarcoma cell lines (A4573,
RD-ES, TC-32, and TC-71) and two control cell lines. Lane 1: DNA molecular weight marker (MW). Lane 2: amplification of b-actin using SK-N-AS mRNA.
Lanes 3–6: RT-PCR with specific primers for the EWS/FLI-1 translocation t(11;22)(q24;q12). Lane 7: HEI-193 is negative for the fusion protein. Sizes for
EWS/FLI-1 transcripts were: 327 base pairs (bps) for type 1; 422 bps for type 2; and 540 bps for type 3. (b) Schematic showing exon joining of the EWS
gene with the FLI-1 gene to generate three different EWS/FLI-1 fusion proteins. (c) Baseline expression of IGF signaling molecules in Ewing’s sarcoma
and control cell lines by Western blot analysis. Baseline IGF-1R levels were analyzed using either a rabbit polyclonal antibody or the human R1507
anti-IGF-1R antibody. P-IGF-1R and IGF-2R were analyzed using appropriate antibodies. IGF- 2 levels in the culture supernatant were also analyzed by
Western blot. Anti-GAPDH was used as a loading control. MCF7 and HEK293 cells were used as positive controls for IGF family member expression. (d)
Steady state levels of p-IRS-1 and total IRS-1 in Ewing’s sarcoma cell lines. Membranes were probed using anti-p-IRS-1, anti-IRS-1, or anti-GAPDH as a
control.
doi:10.1371/journal.pone.0026060.g001
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which results in an arginine at amino acid position 1619 of the
IGF-2 binding domain. These cells also expressed the lowest level
of IGF-2 (Figure 1c). TC-32, TC-71, and RD-ES, which all
express IGF-2, contain the A.G SNP (GG) at nucleotide position
5004 of IGF-2R, which corresponds to a glycine at amino acid
position 1619 (Table 1). This SNP was previously studied in
osteosarcoma [22], but had not been examined in Ewing’s
sarcoma. We did not detect any of the mutations previously
associated with increased IGF-2 expression and response to IGF-
1R inhibitors in the cell lines examined.
TC-71 cells express high levels of IGF-1 and low levels of
IGF-BP3
IGF-BP3 binds both IGF-1 and IGF-2. Most IGF in human
serum is complexed to IGF-BP3 [20,21]. IGF-BP3 inhibits the
interaction of IGFs with IGF-1R. The amount of IGF-1 and IGF-
BP3 secreted into the culture media by Ewing’s sarcoma cell lines
was measured by ELISA. TC-71 cells produced the most IGF-1
(1.603 ng/ml), followed by RD-ES, TC-32, and A4573 (Figure 2a
and Table 1). [As noted above, TC-71 also had the highest level of
IGF-2 (Figure 1c)]. HEI-193 schwannoma cells expressed IGF-1
levels comparable to A4573 cells. This result is not unexpected
since many tumor cell lines produce IGF-1 in vitro and use IGF-1
or IGF-2 as autocrine growth factors [21]. Interestingly, TC-71
cells expressed the lowest amount of IGF-BP3 (0.15 ng/ml,
Figure 2b), which may partially account for its elevated expression
of IGF-1, IGF-2, and p-IGF-1R. The status of members of the
IGF machinery in all four Ewing’s cell lines are summarized in
Table 1.
The effect of R1507 anti-IGF-1R antibody on the
proliferation of Ewing’s sarcoma cell lines
We examined the effect of R1507 on colony formation in
Ewing’s sarcoma cell lines by clonogenic assay (Figure 3a). No
significant decrease in colony number was observed for A4573 and
RD-ES Ewing’s sarcoma cell lines, or for HEI-193 schwannoma
cells (Figure 3a and data not shown). R1507 significantly
decreased colony formation of TC-32 cells starting at 1 mg/ml
(p = 0.025) and TC-71 starting at 5 mg/ml (p = 0.036) (Figure 3a).
Inhibition of colony formation appears to be dose-dependent in
TC-71 cells, whereas colony formation in TC-32 cells drops off
rapidly at 1 mg/ml R1507. TC-71 cells were also treated with high
dose (100 mg/ml) R1507 which resulted in a decrease in colony
formation of 95% (data not shown).
EWS/FLI-1 siRNA transfection decreases colony formation
in TC-71 cells
Because TC-71 cells express the type 1 fusion protein, show a
classic pattern of deregulation of molecules important in the IGF/
IGFR axis (high IGF-1 and -2, low IGF-BP3, high IGF-1R and p-
IGF-1R, high p-IRS-1, and low relative IGF-2R), and are sensitive
to R1507 treatment in the clonogenic assay, they were chosen for
further study. To evaluate the effect of blocking EWS/FLI-1
protein expression on cell growth, TC-71 cells were transfected
with EWS/FLI-1 specific siRNA or non-targeted siRNA
(Figure 3b). Down-regulation of EWS/FLI-1 fusion protein was
confirmed by Western blot for each transfection. TC-71 colony
formation significantly decreased following transfection with
EWS/FLI-1 specific siRNA (p,0.001, Figure 3b). EWS/FLI-1
siRNA inhibited cell growth by 40% compared to cells transfected
with non-targeted siRNA (MTT assay) (p = 0.05, Figure 3c). Two
rounds of transfection with EWS/FLI-1 siRNA resulted in even
greater inhibition of TC-71 cell growth by MTT assay (data not
shown) [23].
EWS/FLI-1 siRNA induces apoptosis of TC-71 cells, while
R1507 does not
TC-71 cells were transfected with transfection reagent alone,
non-targeted siRNA, or EWS/FLI-1 siRNA. Alternatively, cells
were treated with human IgG, or two different concentrations of
R1507. The Annexin V apoptosis assay was used to determine the
percent of cells undergoing apoptosis. EWS/FLI-1 siRNA induced
a significant increase in apoptosis, (27% and 38% at 72 (p= 0.005)
and 96 hours (p = 0.034), respectively), compared to cells trans-
fected with non-targeted siRNA (Figure 3d). In contrast, there was
no significant increase in the percent of TC-71 cells undergoing
apoptosis following treatment with either 25 or 100 mg/ml R1507
compared to a non-specific isotypic control (Figure 3d). Hence,
EWS/FLI-1 siRNA induces apoptosis in TC-71 Ewing’s sarcoma
cells, while R1507 does not. This may be because EWS/FLI-1
siRNA has a wider range of effects than R1507, which inhibits cell
growth mainly due to inhibition of proliferative pathways, rather
Table 1. Characteristics of Ewing’s sarcoma cell lines.
A4573 RD-ES TC-32 TC-71
p-IGF-1R level* ++++ ++ ++ ++++
IGF-1R level* +++ ++ ++ +++
IGF-2R level* ++++ ++++ ++ +++
IGF-2R polymorphism Exon 34 Exon 34 Exon 34 Exon 34
nucleotide 5004 nucleotide 5004 nucleotide 5004 nucleotide 5004
GA, Arg GG, Gly GG, Gly GG, Gly
IGF-1 (ng/ml)(supernatant) 0.35 0.609 0.539 1.603
p-IRS-1 protein level* ++ +++ +++++ ++++
IRS-1 protein level* + +++ ++++ ++++
IGF-BP3 (ng/ml) 0.81 0.72 1.0 0.15
IGF-2* 2 + ++ ++++
EWS/FLI-1 fusion protein Type 3 Type 2 Type 1 Type 1
*Based on densitometry of films, += 5000 pixels.
doi:10.1371/journal.pone.0026060.t001
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than an increase in programmed cell death in this particular cell
line.
EWS/FLI-1 siRNA transfection increases IGF-BP3 and
concomitantly decreases IGF-1 and IGF-2
IGF-BP3 increased 2-fold after EWS/FLI-1 siRNA transfection
in TC-71 cells compared with non-targeted siRNA (p= 0.02,
Figure 4a). This increase occurs presumably because EWS/FLI-1
represses transcription of IGF-BP3 at its promoter through direct
DNA binding, and siRNA to EWS/FLI-1 blocks this repression
[23]. A concomitant 5-fold decrease in the level of IGF-1 in the
supernatant of TC-71 cells (p,0.001) occurs because of the
increased level of IGF-BP3 available to bind IGF-1, and also
because of decreased transactivation of the IGF-1 promoter by
EWS/FLI-1 following transfection with EWS/FLI-1 siRNA
(Figure 4a and b) [24]. IGF-2, which also binds IGF-BP3,
decreases following transfection with EWS/FLI-1 siRNA as
measured by ELISA (n= 12 repeats, p = 0.02, data not shown).
EWS/FLI-1 siRNA transfection and R1507 down-regulate
p-Akt in TC-71 cells
EWS/FLI-1 siRNA inhibited EWS/FLI-1 fusion protein
expression by Western blot as expected (Figure 4c). Total IGF-
1R levels remain unchanged, while p-IGF-1R decreased. P-IRS-1
decreases slightly after exposure to EWS/FLI-1 siRNA compared
to non-targeted siRNA, while total IRS-1 levels remain
unchanged. Akt (protein kinase B) is an important signaling
molecule downstream of IGF-1R [20,21]. Phosphorylation of Akt
indicates the activation of growth stimulatory pathways by IGF.
EWS/FLI-1 siRNA down-regulated p-Akt (ser 473), thus inhib-
iting IGF signaling (Figure 4c, left-hand panel).
R1507 down-regulated total IGF-1R levels because exposure to
anti-IGF-1R antibody causes internalization and degradation of
the receptor (Figure 4c, right-hand panel) [25], which results in
decreased p-IGF-1R. Additionally, R1507 competes with IGF-1
and IGF-2 for binding to the IGF-1R, thus decreasing signaling
(personal communication, K-P Kuenkele). R1507 also decreased
p-IRS-1, and down-regulated Akt phosphorylation in a dose-
dependent manner as a downstream effect resulting from the
decrease in p-IGF-1R, while total IRS-1 and Akt levels remained
unchanged. This inhibition appears to be competitive and
concentration-dependent. Addition of 50 mg/ml rIGF-1 increased
pretreated levels of p-IGF-1R, p-Akt, and p-IRS-1 (lanes 1&4, left
panel, lanes 1&5, right panel, Figure 4c), indicating that this signal
transduction pathway is active in TC-71 cells. rIGF-1 was unable
to fully restore p-Akt or p-IGF-1R to pretreatment levels in the
presence of EWS/FLI-1 siRNA or R1507 (lanes 1&6 left panel,
lanes 1&8 right panel), but p-Akt and p-IGF-1R did increase
slightly in the rIGF-1 plus EWS/FLI-1 siRNA or R1507 treated
cells compared to cells treated with siRNA or R1507 alone
(compare lanes 3&6 left panel and lanes 4&8, right panel,
Figure 4c). The inability of R1507 or EWS/FLI-1 siRNA to
completely abolish p-Akt, especially in the presence of rIGF-1,
indicates that Akt is activated by other pathways in these cells, (e.g.
epidermal growth factor receptor (EGFR) or insulin receptor (IR),
and that a combination of agents, may further reduce activation of
the Akt pathway [10,26–28]. The MAP kinase pathway was not
strongly activated in TC-71 cells, even in the presence of rIGF-1.
Interestingly, R1507 treatment or EWS/FLI-1 siRNA transfection
did not inhibit ERK 1/2 signaling, but rather resulted in increased
ERK 1/2 phosphorylation (Figure 4c), perhaps because an
alternative pathway to IGF was activated.
IGF-1R siRNA down-regulates p-IGF-1R and p-Akt in
TC-71 and HEK 293 (human embryonic kidney) cells
TC-71 and HEK 293 cells were transfected with IGF-1R
siRNA to determine the effect of blocking IGF-1R expression on
the phosphorylation of IGF-1R and Akt. Total IGF-1R levels were
dramatically decreased, total Akt levels remained unchanged,
while p-IGF-1R and p-Akt decreased in both cell lines (high IGF-
1R expressers) (Figure 4d). Therefore, p-IGF-1R and p-Akt can be
markedly down-regulated by decreasing cell-surface IGF-1R in
Figure 2. Baseline levels of IGF-1 and IGF-BP3 in the culture supernatants of four Ewing’s sarcoma cell lines. (a) Baseline IGF-1 levels in
the supernatant of Ewing’s sarcoma and a control cell line. Cells were cultured at a density of 2–106105 per well of a six well plate. After 24 hours,
supernatants were collected and IGF-1 levels were measured using an IGF-1 specific ELISA. Results show the mean and standard error of four
experiments. (b) Baseline IGF-BP3 levels in the supernatant of Ewing’s sarcoma and a control cell line. Cells were cultured as in (a), and supernatants
were collected. Because of the low concentration of IGF-BP3 in the supernatant of Ewing’s cell lines, supernatants were concentrated 406prior to
ELISA. Results show the mean and standard error of three experiments.
doi:10.1371/journal.pone.0026060.g002
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TC-71 and HEK 293. Down-regulation of p-Akt by anti-IGF-1R
antibodies occurs in cells of many different lineages, including
small cell lung cancer (SCLC) [29], acute myeloid leukemia [30],
and non-small cell lung cancer [31].
Discussion
Following failure of front-line therapy, patients with metastatic
Ewing’s sarcoma have limited therapeutic options. Recent clinical
trials have demonstrated that IGF-1R inhibitors can induce
remarkable responses in some patients with advanced disease [4–
9]. The molecular basis of these responses is unclear. The genetic
hallmark of Ewing’s sarcoma is the formation of the aberrant
EWS/FLI-1 transcription factor. Our results suggest that EWS/
FLI-1 siRNA and R1507, a fully human anti-IGF-1R antibody,
inhibit a common IGF signaling pathway that converges on the
suppression of p-Akt. SiRNA to EWS/FLI-1 accomplishes down-
regulation of p-Akt by relieving transcriptional repression of IGF-
BP3 and simultaneously inhibiting IGF-1 transcription [23,24].
This results in a decrease in available IGF-1 (Figure 4b), which
further decreases signaling through the IGF-1R (Figure 5). R1507
exerts its negative impact on Akt phosphorylation by causing
internalization and degradation of total IGF-1R, and by
competing with IGF-1 and IGF-2 for binding to IGF-1R [25].
This in turn results in decreased IGF-1 signaling, decreased p-
IGF-1R, decreased p-IRS-1, and decreased p-Akt. Although many
receptor tyrosine kinases (RTK) signal through the Akt pathway,
treatment with R1507 specifically inhibits signaling through IGF-
1R since R1507 does not cross-react with other receptors. The
decrease in p-Akt after treatment with increasing concentrations of
R1507 reflects the change in phosphorylation due to increasing
IGF-1R inhibition, and is dose-dependent (Figure 4c). Residual
Akt phosphorylation seen after R1507 treatment may be due to
other RTKs, whereas phosphorylation of IGF-1R is inhibited
completely at the lowest dose of R1507 due to its specificity. MAP
kinase signaling was not inhibited by R1507 or EWS/FLI-1
siRNA, however, p-ERK 1/2 levels increased after blocking the
IGF-1 pathway with R1507 or EWS/FLI-1 siRNA, perhaps as a
compensatory signaling pathway. Hence both agents work to
inhibit the proliferation of Ewing’s sarcoma cells by inhibiting
Figure 3. Inhibition of growth and induction of apoptosis in Ewing’s sarcoma cell lines treated with R1507 or EWS/FLI-1 siRNA. (a)
The effect of R1507 on the growth of four Ewing’s sarcoma cell lines as assessed by clonogenic assay. Cells were treated with 1–50 mg/ml R1507 for
one week. Colonies were counted and compared to control dishes (100% growth). Results show mean and standard error of 4 experiments. (b) TC-71
cell growth is inhibited by siRNA to the EWS/FLI-1 fusion protein. Cells were transfected with tranfection reagent alone, 50 nM non-targeted siRNA, or
50 nM EWS/FLI-1 siRNA once at the beginning of culture and allowed to grow for one week. Colonies were counted and compared to control dishes
(non-targeted siRNA). Results show mean and standard error of three experiments. (c) The effect of EWS/FLI-1 siRNA on the growth of TC-71 cells as
assessed by MTT assay. TC-71 cells were transfected with transfection reagent alone, 50 nM non-targeted siRNA, or 50 nM EWS/FLI-1 siRNA. After
48 hours, conversion of MTT was measured and is expressed as change in cell growth as compared to transfection reagent alone (100% growth). The
mean and standard error of four experiments is shown. (d) Apoptosis of TC-71 cells following transfection with EWS/FLI-1 siRNA or treatment with
R1507. TC-71 cells were either transfected with reagent alone, 50 nM non-targeted siRNA, or 50 nM EWS/FLI-1 siRNA. Alternatively, they were treated
with human isotypic control IgG (100 mg/ml) or R1507 (25 or 100 mg/ml) for 48, 72, and 96 hours. Cells were stained with Annexin V-FITC and
propidium iodide and analyzed by FACS analysis. The mean and standard error of three experiments is shown.
doi:10.1371/journal.pone.0026060.g003
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phosphorylation of Akt, albeit via different upstream mechanisms
(Figure 5).
Ewing’s sarcoma cell lines bearing type 1 EWS/FLI-1 fusion
proteins have been postulated to be less virulent than their type 2-
and 3- expressing counterparts [32] and patients bearing the type
1 fusion protein were thought to have an improved outcome
compared to those expressing other fusion protein types [33].
Interestingly, TC-32 and TC-71 cells express the type 1 fusion
protein and are the most sensitive to R1507 by clonogenic assay.
Similar results were found in a phase I clinical trial with AMG 479
(Amgen), another anti-IGF-1R monoclonal antibody (J Rodon,
personal communication) [8]. However, the majority of Ewing’s
sarcoma patients express the type 1 fusion protein [33,34], while
the response rate to anti-IGF-1R antibodies is considerably lower.
More recent publications have failed to confirm this association
[35,36]. Some authors suggest that variability of transcriptional
targets of the different fusion proteins could account for some of
the clinical differences [32]. Why some patients respond to anti-
IGF-1R antibodies and others do not is much more complicated
than just the type of fusion protein they harbor (Table 1).
The degree of inhibition of Ewing’s sarcoma cell growth by
R1507 may vary with assay conditions (K-P Kuenkele, personal
communication). This may confound the preclinical assessment of
how the expression pattern of various members of the IGF system
in Ewing’s sarcoma cell lines relate to responsiveness to R1507
and/or other IGF-1R inhibitors [10]. Indeed, total IGF-1R
expression level was not predictive of a response to R1507 in our
cell lines, as previously reported for a different anti-IGF-1R
Figure 4. EWS/FLI-1 and R1507 influence the activation/expression of key molecules in the IGF-1 signaling pathway. (a) IGF-BP3 levels
increase following transfection of TC-71 cells with EWS/FLI-1 siRNA. TC-71 cells were transfected with reagent alone, 50 nM non-targeted (NT) siRNA,
or 50 nM EWS/FLI-1 siRNA for 48 hours. After three days total in culture, the supernatant was concentrated 206. An ELISA for IGF-BP3 was performed.
Results show the mean and standard error of four experiments. Starting amounts of IGF-BP3 are higher than those in Figure 2 because of the longer
culture time required for transfection experiments. (b) IGF-1 levels decrease in EWS/FLI-1 siRNA-transfected TC-71 cell supernatant. TC-71 cells were
transfected with 50 nM siRNA for 48 hours. Media was collected and concentrated 206. IGF-1 ELISA was performed. Results show the mean and
standard error of four experiments. (c) The effect of EWS/FLI-1 siRNA and R1507 on the expression of various molecules involved in IGF signaling
pathways in TC-71 cells. Left-hand panel: TC-71 cells were transfected with reagent alone (C), 100 nM non-targeted siRNA (NT), or 100 nM EWS/FLI-1
siRNA (E/F) for 48 hours as described. Western blot analysis was performed using antibodies directed at molecules important in IGF signaling
pathways. Anti-GAPDH was used as a loading control. Experiments were performed in the presence or absence of 50 mg/ml rIGF-1. Right-hand panel:
TC-71 cells were treated with 0–100 mg/ml R1507 for 24 hours. Cells were harvested for Western blot and probed with relevant antibodies.
Experiments were performed in the presence or absence of 50 mg/ml rIGF-1. (d) IGF-1R siRNA down-regulates total IGF-1R, p-IGF-1R, and p-Akt. HEK
293 and TC-71 cells were transfected with 100 or 50 nM siRNA against IGF-1R, respectively, for 48 hours. Cell lysates were harvested and Western blot
was performed using antibodies to IGF-1R, p-IGF-1R, total Akt, and p-Akt (ser 473). SiRNA against GAPDH was used as a control.
doi:10.1371/journal.pone.0026060.g004
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antibody (h7C10, Merck) in rhabdomyosarcoma and R1507 and
AMG479 in osteosarcoma [37–39].
IGF-2R acts as a classic tumor suppressor gene in several
different types of cancer [40–47], but its relevance in Ewing’s
sarcoma is unknown. Several mutations inactivate and/or down-
regulate IGF-2R [16,40,42,45], resulting in increased levels of
IGF-2, and increased signaling through IGF-1R [40–47]. We did
not detect these specific mutations in our cell lines. It remains
unclear whether the GG SNP in the IGF-2 binding domain of
IGF-2R is causally related to the higher levels of IGF-2 in TC-32
and TC-71, or if other factors are involved. This topic merits
further investigation because preclinical studies have shown that
several cancers expressing high levels of IGF-2 due to IGF-2R
mutation and loss of heterozygosity (LOH) are more responsive to
both anti-IGF-1R antibodies and anti-sense directed against IGF-2
or IGF-1R [43–46]. IGF-2R gene status has also been used to
determine the course of treatment in head and neck cancer [42].
In conclusion, both EWS/FLI-1 siRNA and R1507 inhibit
cellular proliferation by targeting a common pathway, namely the
down-regulation of p-IGF-1R and p-Akt (Figure 5). The
involvement of this pathway may explain why some patients with
Ewing’s sarcoma demonstrate marked responses to anti-IGF-1R
antibodies [4–9]. However, a limitation of the hypothesis
presented in Figure 5 is that different cell lines and/or patients
may demonstrate divergent signaling. Our data is consistent with
that of previously published studies demonstrating down-regula-
tion of p-Akt in sarcoma xenografts [38,39]. EWS/FLI-1 siRNA
appears to have more apoptotic activity than R1507 because it
(siRNA) up-regulates IGF-BP3, which can also induce apoptosis
independently of the IGF system, perhaps through nucleo-
mitochondrial translocation of RXRa/Nur77 [48]. Further studies
are needed to elucidate resistance mechanisms since not all
Ewing’s sarcoma patients are responsive. These resistance
mechanisms may involve differences in various parts of the
IGF/IGFR signaling complex, and may also include the
inactivation of tumor suppressor genes including p53, WT1, and
PTEN. Alternatively, resistance to anti-IGF-1R treatment in
Ewing’s sarcoma could be related to the activation of alternate
signaling pathways including EGFR and IR [10,26–28]. Under-
standing mechanisms of activity, resistance, and the role of
combination therapy, including conventional agents or newer
molecules that target signals downstream of IGF/IGFR or that
interfere with EWS/FLI-1 function [49,50], will be paramount to
improving on the promise of success seen thus far.
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